Under the deal, financial terms of which were not disclosed, Oynx will develop all the necessary chemistry protocols and produce supplies of the active pharmaceutical ingredient for upcoming Phase I trials.
Oynx said that project, which is expected to take around seven months to complete, will focus on improving methodologies developed by the charity with the emphasis being the creation of a more efficient and cost-effective route.
In a press statement Dr Nigel Westwood, drug supply manager at Cancer Research UK, said: “Having had a very positive experience of using Onyx Scientific’s process development and GMP manufacturing services in the past, they seemed like a strong candidate for this important project.
“Despite the fact that Cancer Research UK had to change suppliers at such a critical stage, Onyx Scientific still expect to bring the project in on time and on budget. Given their expertise in chemistry and ability to deliver, we believe they are perfect fit for the project,” added Dr Westwood.